NASDAQ:KRYS Krystal Biotech - KRYS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $77.89 +3.66 (+4.93%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$73.02▼$78.0650-Day Range$72.39▼$84.2752-Week Range$47.67▼$89.59Volume197,430 shsAverage Volume224,926 shsMarket Capitalization$2.01 billionP/E RatioN/ADividend YieldN/APrice Target$119.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Krystal Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside53.1% Upside$119.25 Price TargetShort InterestBearish5.71% of Float Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.61Based on 2 Articles This WeekInsider TradingSelling Shares$7.34 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.78) to ($2.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.39 out of 5 starsMedical Sector180th out of 989 stocksBiological Products, Except Diagnostic Industry24th out of 166 stocks 3.5 Analyst's Opinion Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $119.25, Krystal Biotech has a forecasted upside of 53.1% from its current price of $77.89.Amount of Analyst CoverageKrystal Biotech has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.71% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Krystal Biotech has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKrystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Krystal Biotech is -0.87. Previous Next 3.1 News and Social Media Coverage News SentimentKrystal Biotech has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Krystal Biotech this week, compared to 1 article on an average week.Search Interest19 people have searched for KRYS on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,344,570.00 in company stock.Percentage Held by Insiders17.80% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.80% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Krystal Biotech are expected to grow in the coming year, from ($5.78) to ($2.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is -14.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is -14.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 3.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Krystal Biotech (NASDAQ:KRYS) StockKrystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases. Its platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 that is optimized for local and repeat gene transfer to epithelial cells, and initially using its platform to develop treatments for rare or orphan monogenic diseases caused by the absence of or a mutation in a single gene. It is also involved in leveraging its platform to develop novel therapies to treat more prevalent conditions, and also focuses on developing treatments for use in the setting of aesthetic skin conditions. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.Read More Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address KRYS Stock News HeadlinesMarch 18, 2023 | americanbankingnews.comShort Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Expands By 6.3%March 6, 2023 | finance.yahoo.comKrystal Biotech Appoints Catherine Mazzacco to Board of DirectorsMarch 25, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 6, 2023 | finance.yahoo.comKrystal Biotech Appoints Catherine Mazzacco to Board of DirectorsMarch 3, 2023 | benzinga.comKrystal Biotech Stock (NASDAQ:KRYS), Guidance and ForecastMarch 2, 2023 | finance.yahoo.comKrystal Biotech to Present at the 43rd Annual TD Cowen Health Care ConferenceFebruary 28, 2023 | markets.businessinsider.comGuggenheim Reaffirms Their Buy Rating on Krystal Biotech (KRYS)February 28, 2023 | markets.businessinsider.comExpert Ratings for Krystal BiotechMarch 25, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...February 28, 2023 | cnbc.comBuy this little-known biotech stock set to rally nearly 60% as use of gene therapy grows, Goldman Sachs saysFebruary 28, 2023 | markets.businessinsider.comKrystal Biotech (KRYS) was upgraded to a Buy Rating at Goldman SachsFebruary 27, 2023 | msn.comKrystal Biotech GAAP EPS of -$1.25 misses by $0.26February 27, 2023 | finance.yahoo.comKrystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational ProgressJanuary 20, 2023 | seekingalpha.comKrystal Biotech: Reached My Price Target, Waiting For A DropJanuary 18, 2023 | finance.yahoo.comKrystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic FibrosisJanuary 10, 2023 | msn.comFDA extends review of Krystal's topical gene therapy for skin disorder citing manufacturing dataJanuary 9, 2023 | finance.yahoo.comKrystal Biotech's decision date for experimental treatment drug receives 3-month delay from FDAJanuary 9, 2023 | markets.businessinsider.comKrystal Biotech Announces FDA's 3-Month Extension Of BLA PDUFA Date And Regulatory Update For B-VECJanuary 9, 2023 | finance.yahoo.comKrystal Biotech’s stock is down on delayed PDUFA dateJanuary 9, 2023 | finance.yahoo.comKrystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis BullosaDecember 16, 2022 | finance.yahoo.comBofA Securities: The most promising biotech stocks in 2023December 15, 2022 | finance.yahoo.comKrystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of MedicineDecember 14, 2022 | finance.yahoo.comNew England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis BullosaDecember 12, 2022 | finance.yahoo.com12 Best Small-Cap Healthcare Stocks To Buy NowDecember 6, 2022 | finance.yahoo.com2 Risky Stocks That Could Soar in 2023December 5, 2022 | finance.yahoo.comJeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic ConferenceDecember 1, 2022 | finance.yahoo.comKrystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address KRYS Company Calendar Last Earnings2/27/2023Today3/24/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRYS CUSIPN/A CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees119Year Founded2017Price Target and Rating Average Stock Price Forecast$119.25 High Stock Price Forecast$133.00 Low Stock Price Forecast$101.00 Forecasted Upside/Downside+53.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($5.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-21.19% Return on Assets-19.55% Debt Debt-to-Equity RatioN/A Current Ratio13.30 Quick Ratio13.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.28 per share Price / Book3.84Miscellaneous Outstanding Shares25,760,000Free Float21,178,000Market Cap$2.01 billion OptionableNot Optionable Beta0.87 Social Links Key ExecutivesKrish S. KrishnanChairman, President & Chief Executive OfficerSuma M. KrishnanDirector, President-Research & DevelopmentGeorge ChenManager-Information Technology & CSVTrevor ParrySenior Director-Scientific AffairsDavid GlynnGeneral Counsel & Head-Commercial & ComplianceKey CompetitorsRelay TherapeuticsNASDAQ:RLAYRevolution MedicinesNASDAQ:RVMDImmunovantNASDAQ:IMVTSpringWorks TherapeuticsNASDAQ:SWTXImmunocoreNASDAQ:IMCRView All CompetitorsInsiders & InstitutionsVictory Capital Management Inc.Bought 35,732 shares on 3/10/2023Ownership: 1.317%Dino A RossiSold 40,000 sharesTotal: $3.33 M ($83.25/share)Voya Investment Management LLCSold 1,280 shares on 2/28/2023Ownership: 0.243%NatixisBought 4,000 shares on 2/24/2023Ownership: 0.016%Alliancebernstein L.P.Bought 600 shares on 2/16/2023Ownership: 0.101%View All Insider TransactionsView All Institutional Transactions KRYS Stock - Frequently Asked Questions Should I buy or sell Krystal Biotech stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRYS shares. View KRYS analyst ratings or view top-rated stocks. What is Krystal Biotech's stock price forecast for 2023? 4 equities research analysts have issued twelve-month price targets for Krystal Biotech's shares. Their KRYS share price forecasts range from $101.00 to $133.00. On average, they predict the company's share price to reach $119.25 in the next year. This suggests a possible upside of 53.1% from the stock's current price. View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts. How have KRYS shares performed in 2023? Krystal Biotech's stock was trading at $79.22 at the beginning of 2023. Since then, KRYS stock has decreased by 1.7% and is now trading at $77.89. View the best growth stocks for 2023 here. When is Krystal Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our KRYS earnings forecast. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) released its earnings results on Monday, February, 27th. The company reported ($1.25) earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $0.01. What ETFs hold Krystal Biotech's stock? ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD), Franklin Genomic Advancements ETF (HELX), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Harbor Disruptive Innovation ETF (INNO). What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA). When did Krystal Biotech IPO? (KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO. What is Krystal Biotech's stock symbol? Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS." Who are Krystal Biotech's major shareholders? Krystal Biotech's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avoro Capital Advisors LLC (5.48%), Lord Abbett & CO. LLC (4.96%), Frazier Life Sciences Management L.P. (3.88%), Credit Suisse AG (2.65%), Point72 Asset Management L.P. (2.16%) and First Light Asset Management LLC (1.84%). Insiders that own company stock include Dino A Rossi, Krish S Krishnan and Suma Krishnan. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Krystal Biotech's stock price today? One share of KRYS stock can currently be purchased for approximately $77.89. How much money does Krystal Biotech make? Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $2.01 billion. The company earns $-139,980,000.00 in net income (profit) each year or ($5.51) on an earnings per share basis. How many employees does Krystal Biotech have? The company employs 119 workers across the globe. How can I contact Krystal Biotech? Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com. This page (NASDAQ:KRYS) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.